Publication Topic

Schenfeld J, Gong T, Henry D, Kelsh M, Gawade P, Peng Y, Bradbury BD, Li S. 2022. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 30(7):6327–6338; doi: 10.1007/s00520-022-06967-x. PMID: 35482126.

Gillezeau C, Movva N, van Gerwen M, Rabon-Stith K, Shire N, Brohawn PZ, Taioli E, Fryzek J. 2022. Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients. PLoS One 17(8):e0271339; doi: 10.1371/journal.pone.0271339. PMID: 36040901.

Bylsma L, Fryzek J, Movva N, Frankenfeld C, Hooda N, Pundole X, et al. 2022. Systematic literature review of the prevalence and prognostic value of delta-like ligand 3 protein expression in small cell lung cancer. PROSPERO 2022 CRD42022351119

Anneberg M, Svane HML, Fryzek J, Nicholson G, White JB, Edris B, Smith LM, Hooda N, et al. 2022. The epidemiology of desmoid tumors in Denmark. Cancer Epidemiol 77(April):102114; doi: 10.1016/j.canep.2022.102114. PMID: 35121405.

Hooda N, Svane HML, Fryzek J, Nicoholson G, White JB, Edris B, Smith LM, Petersen MM, et al. The epidemiology of desmoid tumors in Denmark. Poster presented at the Connective Tissue Oncology Society Annual Meeting, November 2021.

Frankenfeld CL, Leslie TF, Menon NM. 2021. Longer time-to-treatment but better survival for colorectal cancer patients presumptively not diagnosed in a hospital. Cancer Causes Control 32(10):1185–1191; doi: 10.1007/s10552-021-01464-8. PMID: 34160709.

Hackshaw A, Cohen SS, Reichert H, Kansal AR, Chung KC, Ofman JJ. 2021. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. Brit J Cancer 125(10):1432-1442; doi: 10.1038/s41416-021-01498-4. PMID: 34426664.

Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. 2021. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: A systematic review and meta-analysis. Oncologist 26(9):e1609–e1618; doi: 10.1002/onco.13822. PMID: 33973301.

Hathway J, Miller-Wilson L, Sharma A, Jensen I, Yao W, Raza S, et al. 2021. The impact of increasing multitarget stool DNA use among colorectal cancer screeners in a self-insured US employer population. J Mark Access Health Policy, 9(1):1948670; doi: 10.1080/20016689.2021.1948670.

Gillezeau C, Movva N, Fryzek J, Rabon-Stith K, Brohawn PZ, Gerwen M van, Taioli E. Molecular epidemiology study of interferon gamma (IFN-γ) expression in urothelial bladder cancer (UBC). Poster presentation, 37^th ICPE (International Conference on Pharmacoepidemiology & Therapeutic Rick Management), virtual conference, August 2021.